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Menthol and other counterstimuli relieve itch, result-
ing in an antipruritic state that persists for minutes to
hours. However, the neural basis for this effect is un-
clear, and the underlying neuromodulatory mecha-
nisms are unknown. Previous studies revealed that
Bhlhb5/ mice, which lack a specific population of
spinal inhibitory interneurons (B5-I neurons), develop
pathological itch. Here we characterize B5-I neurons
and show that they belong to a neurochemically
distinct subset. We provide cause-and-effect evi-
dence that B5-I neurons inhibit itch and show that
dynorphin, which is released from B5-I neurons, is
a key neuromodulator of pruritus. Finally, we show
that B5-I neurons are innervated bymenthol-, capsa-
icin-, and mustard oil-responsive sensory neurons
and are required for the inhibition of itch by menthol.
These findings provide a cellular basis for the inhibi-
tion of itch by chemical counterstimuli and suggest
that kappa opioids may be a broadly effective ther-
apy for pathological itch.
INTRODUCTION
Itch, like pain, is an aversive sensation that warns us of potential
threats to the body (Ross, 2011; Bautista et al., 2014). However,
itch is a distinct sensation, characterized by the desire to
scratch. Although scratching may remove irritants from the
skin (providing at least transient relief from itch), it has the para-
doxical effect of causing tissue damage that potentiates itchthrough release of inflammatory mediators. This pathological
itch-scratch-itch cycle is a hallmark of chronic pruritus, which
can be just as debilitating as chronic pain (Weisshaar and Dal-
gard, 2009; Yosipovitch, 2008). Unfortunately, there are few ther-
apeutic options for those that suffer from severe pathological
itch. Whereas mu opioids such as morphine are highly effective
for the treatment of pain, these drugs actually worsen itch (Ko
and Naughton, 2000; Szarvas et al., 2003). Thus, there is a great
need for better therapies to treat intractable pruritus.
One reason that itch has lagged behind pain in terms of effec-
tive therapies is because, until recently, we lacked a clear under-
standing of how itch is detected and encoded in the nervous
system. However, over the last few years there has been much
progress in this field. There is now good evidence that
MrgprA3-expressing sensory neurons selectively mediate itch,
even when activated by the classic algogen capsaicin (Han
et al., 2013). It is very likely that these are not the only itch-selec-
tive fibers, since histamine-dependent itch appears to be medi-
ated by a different subset of sensory neurons (Roberson et al.,
2013). Next, itch seems to be relayed by at least two populations
of spinal interneurons—those that express the Npra receptor
and those that express the gastrin-releasing peptide receptor
(GRPR)—before being conveyed to the brain where it is
consciously perceived (Mishra andHoon, 2013; Sun et al., 2009).
Menthol and other forms of counterstimulation, such as
scratching, heat, cool, and noxious agents, provide relief of itch
that begins almost instantaneously and lasts from minutes to
hours (Ward et al., 1996; Yosipovitch et al., 2007; Bromm et al.,
1995). This relief occurs evenwhen thecounterstimulus is applied
at great distances from the source of itch sensation (Nilsson et al.,
1997). Together, these psychophysical observations suggest
that crossmodal inhibition occurs centrally, possibly within the
spinal dorsal horn, where sensory information is first integrated
and modulated (Todd, 2010). The instantaneous relief of itchNeuron 82, 573–586, May 7, 2014 ª2014 The Authors 573
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Cellular Basis for the Inhibition of Itchexperienced upon scratching is presumably mediated by a fast-
acting neurotransmitter (Akiyama et al., 2011). In contrast, pro-
longed inhibition is thought to involve neuromodulators, but the
nature of such neuromodulation remains elusive and the neural
basis for inhibition of itch by counterstimuli is not known.
We previously generated a mouse model of pathological
chronic itch through the constitutive deletion of Bhlhb5 (also
known as Bhlhe22), a transcription factor that is transiently ex-
pressed in several neuronal subtypes during embryonic and early
postnatal development (Ross et al., 2010, 2012). Through selec-
tive ablation, we provided strong evidence that the pathological
itch in Bhlhb5mutant mice was due to loss of Bhlhb5 in inhibitory
neurons in the spinal dorsal horn. Using fate-mapping ap-
proaches, we found that Bhlhb5 mutant mice lack a subset of
inhibitoryneurons in laminae I and II (Rosset al., 2010). Thesefind-
ings suggested that Bhlhb5 is essential for the survival of a set
of spinal inhibitory interneurons (termed B5-I neurons) that are
required for normal itch sensation. However, the identity of B5-I
neurons was not clear, and how they inhibit itch was not known.
Here we provide evidence that acute inhibition of B5-I neurons
results in elevated itch. We identify and characterize B5-I neu-
rons, showing that they correspond to specific neurochemically
defined populations and that they release the kappa opioid dy-
norphin. Our data suggest that kappa agonists act locally within
the spinal cord to selectively reduce itch and not pain. We find
that B5-I cells are directly innervated by primary afferents that
respond to counterstimuli, such as heat and coolness, which
relieve itch in humans. Moreover, we show that menthol inhibits
itch in wild-type mice but does not do so in mice lacking B5-I
neurons. Thus, B5-I neurons may mediate the inhibition of itch
by chemical counterstimuli.
RESULTS
Acute Inhibition of B5-I Cells Results in Elevated Itch
We previously showed that Bhlhb5 is needed for survival of spi-
nal inhibitory interneurons that are required for normal itch
sensation (Ross et al., 2010). To more specifically identify these
neurons, we performed coimmunostaining for Bhlhb5 and
markers that define distinct populations of spinal interneurons.
Bhlhb5 is transiently expressed in 7% of neurons in the dorsal
horn of mice from embryonic day 13.5 to postnatal day 10 (P10),
so we performed these experiments using P4 mice. Consistent
with our previous report (Ross et al., 2010), we found that
three-quarters of Bhlhb5-expressing neurons in superficial dor-
sal horn (laminae I and II) are inhibitory, as shown by coexpres-
sion of Pax2 (Figure 1A). We refer to these Bhlhb5-expressing
inhibitory interneurons as B5-I neurons.
The somatostatin receptor sst2A is exclusive to inhibitory neu-
rons in superficial dorsal horn and is found in50% of the inhib-
itory interneurons in this region (Polga´r et al., 2013a, 2013b; Todd
et al., 1998; Yasaka et al., 2010). To determine whether the B5-I
neurons belonged to this subset, we used antibodies against
Bhlhb5, Pax2, and sst2A. This immunostaining showed that the
vast majority of B5-I neurons (90%) coexpressed the somato-
statin receptor sst2A (Figures 1A and S1A available online).
Furthermore, when we recorded from spinal interneurons genet-
ically labeled with the Bhlhb5-cre allele (Ross et al., 2010), half574 Neuron 82, 573–586, May 7, 2014 ª2014 The Authorsshowed strong hyperpolarization in response to somatostatin
(Figure 1B), confirming that B5-I neurons express functional
sst2A receptors. Given the loss of B5-I neurons in Bhlhb5
/
mice, we reasoned that there would be a corresponding
decrease in the number of sst2A-expressing neurons in these
animals. As predicted, the number of sst2A-expressing neurons
was reduced by two-thirds in Bhlhb5/mice, with no significant
change in the number of sst2A-negative inhibitory neurons (Fig-
ures 1C and 1D). Thus, the vast majority of B5-I neurons belong
to the subset of inhibitory spinal interneurons that express sst2A,
and a large proportion of the sst2A-expressing population is
missing in Bhlhb5/ mice.
Since somatostatin inhibits neuronal activity and sst2A is the
only somatostatin receptor that is expressed by dorsal horn neu-
rons (see http://www.brain-map.org), the finding that B5-I neu-
rons express sst2A allowed us to directly test the idea that B5-I
neurons normally function to inhibit itch. This experiment was
important because, although we had previously shown that
loss of B5-I neurons during development is associated with
abnormally elevated itch (Ross et al., 2010), the evidence was
merely correlative. Specifically, it was not clear whether B5-I
neurons function in the adult to inhibit itch, or whether B5-I neu-
rons play a key developmental role in the formation of proper itch
circuits. We hypothesized that if B5-I neurons normally function
to inhibit itch, then acute inhibition of these neurons by somato-
statin would increase itch sensitivity (Figure 1E). Indeed, upon
intrathecal injection of the somatostatin analog octreotide, we
observed vigorous scratching, biting, and licking behavior that
was suggestive of itch (Figure 1F), consistent with previous re-
ports (Seybold et al., 1982). This spontaneous behavior was
dose dependent, with an immediate onset and a duration of
approximately half an hour.
Because B5-I neurons account for the majority (two-thirds) of
sst2A-expressing cells, the finding that acute treatment with oc-
treotide results in elevated scratching behavior is consistent with
the hypothesis that B5-I neurons inhibit itch. Nevertheless, it re-
mained possible that the observed scratching behavior was due
instead to the effect of octreotide on the one-third of sst2A-ex-
pressing neurons that are not B5-I neurons. We therefore tested
the effect of octreotide on Bhlhb5/ mice, which lack B5-I neu-
rons. Specifically, we reasoned that, if octreotide-induced
scratching is due to inhibition of B5-I neurons, this treatment
would have no effect in mice that lack these cells. As predicted,
we observed very little scratching behavior upon intrathecal in-
jection of 100 nM octreotide in Bhlhb5/ mice (Figure 1F).
This finding strongly suggests that octreotide-induced itch
behavior is due to inhibition of B5-I neurons.
To further assess whether the octreotide-induced scratching
was due to elevated itch (rather than a nociceptive response or
a grooming behavior), we tested the effect of octreotide on pru-
ritogen-evoked itch. For these experiments, we selected a very
low dose of octreotide that had no significant effect on its own
(3 ng) and tested its effect on chloroquine-induced itch. We
found that intrathecal octreotide significantly increased the
amount of time that mice spent biting at the injection site in
response to intradermal chloroquine (Figure 1G). In contrast,
this dose of intrathecal octreotide had no effect on acute noci-
ceptive reflexes, as measured by hindpaw withdrawal latency
Figure 1. Acute Inhibition of B5-I Cells Results in Elevated Itch
(A) The inhibitory subset of Bhlhb5-expressing neurons in the superficial dorsal horn (B5-I neurons) coexpress sst2A. Spinal cord sections from P4 mice were
immunostained to reveal Bhlhb5 (green), sst2A (red), and the inhibitory marker Pax2 (blue). The vast majority (90%) of cells expressing Bhlhb5 and Pax2 in
laminae I and II colabel with sst2A (arrows). A single confocal optical section through laminae I-IIo is shown. Scale bar, 20 mm.
(B) Outward current was observed upon application of somatostatin (SST, 1 mM) to 50% of cells with the Bhlhb5-cre allele. (Note that the Bhlhb5-cre allele also
labels other populations including excitatory neurons, which do not respond to SST.)
(C) The number of sst2A-expressing neurons in dorsal horn is significantly diminished inBhlhb5
/mice. Spinal cord sections from4- to 5-week-oldwild-type (top) or
Bhlhb5/ (bottom)micewere immunostained to reveal sst2A (green) andPax2 (magenta). Approximately half of the inhibitory (Pax2-expressing) neurons in laminae I
and II express sst2A in wild-typemice (arrows), and these cells are dramatically reduced inBhlhb5mutantmice. A single optical section is shown. Scale bar, 50 mm.
(D) Quantification of (C). There is a significant reduction (*p < 0.05) in the number of sst2A-expressing neurons (sst2A +ve) in laminae I-II of the dorsal horn in
Bhlhb5/ relative to wild-type (WT), with no significant change (NS) in the number of Pax2-positive inhibitory interneurons that do not express sst2A (sst2A –ve).
Data are represented asmean + SD number of cells in laminae I-II per dorsal horn through 100 mmcord taken from L4 (n = 6mice per genotype, 2 dorsal horns per
mouse), analyzed by two-way ANOVA followed by pairwise comparison using the Holm-Sidak method.
(E) Schematic depicting inhibition of sst2A-expressing interneurons with the somatostatin analog octreotide, resulting in elevated itch.
(F) Intrathecal administration of octreotide (3, 10, 30, or 100 ng in 5ml vehicle) dosedependently evoked spontaneous scratchingbehavior inwild-typemice (n =6–8
mice/treatment). Bhlhb5/ mice receiving 100 ng of octreotide intrathecally showed very little scratching response. Intrathecal injections were confirmed by
coinjection of 10%methylene blue (n = 8mice). Total scratching bouts (mean±SEM)weremeasuredover a 30min observation period. One-way ANOVAwas used
to compare mean scratch bouts between treatment groups followed by Tukey’s post hoc test (* indicates significantly different than PBS, p < 0.05).
(G) Pruritogen-induced itch behavior was significantly enhanced following intrathecal octreotide (3 ng). Chloroquine (100 mg) was injected intradermally in the calf
30 min after treatment with either octreotide (i.t.) or vehicle (PBS; i.t.). Itch behavior was defined as the cumulative amount of time spent biting/licking the injection
site over 30min. Data are represented asmean ± SEM (*p < 0.05, Student’s t test). Also see Figure S1 for the specificity of octreotide-mediated behavioral effects.
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Figure 2. B5-I Neurons Belong to a Population that Expresses Galanin and/or nNOS
(A) The vast majority (95.4%, range 95.3%–95.7%, n = 3) of galanin-immunoreactive cells in laminae I-II (magenta) were Bhlhb5 immunoreactive (green; double
arrow), and galanin-expressing cells accounted for 78.1% (range: 72.8%–86.4%) of B5-I neurons (image from lamina I-IIo). Numerous nNOS-immunoreactive
cells (magenta) coexpress Bhlhb5 (green) as shown by the arrow (n = 3, image from lamina I). NPY seldom colocalized with Bhlhb5 (2.3% of NPY cells,
range 1.1%–4.7%, n = 3; arrowheads illustrate cells that do not colocalize, lamina II). Images are single confocal optical sections from mice of indicated ages.
(B) Populations of inhibitory interneurons in laminae I-II of adult dorsal horn. Approximately 54% of these cells express sst2A (sst2A positive), and these can be
further subdivided into classes based on expression of galanin (red), nNOS (blue), galanin and nNOS (magenta), or sst2A only (neither galanin nor nNOS; green).
B5-I neurons belong to the classes that express galanin and/or nNOS.
(C) Single optical sections of laminae I-II from wild-type or Bhlhb5/ mice reveal a dramatic loss of the sst2A-expressing cells that contain galanin (red, double-
headed arrow) and nNOS (blue, arrows), while the sst2A-expressing cells that contain neither galanin nor nNOS (sst2A only) are still present (arrowheads).
Scale bar, 20 mm.
(D) Quantification of (C) showing a significant reduction in cells expressing galanin (red), nNOS (blue), and galanin/nNOS (magenta). There was no significant
change (NS) in the number of cells expressing sst2A alone (green). Data are represented as mean + SD number of cells in laminae I-II per dorsal horn through
100 mm cord taken from L4 (n = 6 mice, genotype, 2 dorsal horns/mouse), analyzed by two-way ANOVA followed by pairwise comparison using the Holm-Sidak
method (* indicates p < 0.05). See Figure S2 for large field views.
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octreotide was very likely mediated by spinal neurons (rather
than the central terminals of primary afferents) since intradermal
octreotide caused no itch-like behavior (Figure S1C). Together,
these findings suggest that acute inhibition of B5-I neurons re-
sults in elevated itch.
Neurochemical Identification of B5-I Neurons
Sst2A-expressing inhibitory neurons in laminae I-II can be further
subdivided based on the presence or absence of galanin and
neuronal nitric oxide synthase (nNOS), which are expressed in
mostly nonoverlapping subsets (Figure 2B; Iwagaki et al.,
2013; Tiong et al., 2011). To investigate whether B5-I neurons
constitute one or more of these subsets, we performed immuno-
staining experiments. These experiments revealed that virtually
all (95%) of the galanin-expressing cells coexpress Bhlhb5
and that these account for 78% of the B5-I neurons (Figures
2A, left, and S2A). Likewise, many nNOS-expressing neurons
coexpress Bhlhb5 (though the number is difficult to assess since
nNOS is beginning to be expressed just as Bhlhb5 is being
downregulated; Figures 2A, middle, and S2B). In contrast,
Bhlhb5 was very seldom coexpressed with neuropeptide Y576 Neuron 82, 573–586, May 7, 2014 ª2014 The Authors(NPY), a marker for a distinct inhibitory subpopulation (2% of
NPY cells; Figures 2A, right, and S2C). These findings suggest
that B5-I neurons correspond to two, mostly nonoverlapping
subpopulations of inhibitory interneurons: those that express
galanin and those that express nNOS.
We next investigatedwhat happens to these populations in the
Bhlhb5/ mouse. Mice lacking Bhlhb5 showed a dramatic loss
of galanin- and nNOS-expressing populations, but there was no
difference in the distribution of two other populations of inhibitory
interneuronsmarked by NPY and parvalbumin, respectively (Fig-
ure S2D). To investigate this finding in more detail, we performed
a quantitative analysis with the optical disector method (Polga´r
et al., 2004) on sections reacted for sst2A, nNOS, galanin, and
NeuN and stained with a nuclear marker (Figures 2B–2D and
S2E). In wild-type mice, four subpopulations of sst2A-expressing
cells were identified: the first coexpressed galanin, a second
coexpressed nNOS, a third (small) subpopulation coexpressed
both galanin and nNOS, and a fourth expressed neither galanin
nor nNOS (Figure 2B). In theBhlhb5/mice, galanin-expressing
cells were almost completely absent, while the number of sst2A-
expressing cells that contained nNOS but not galanin was sub-
stantially reduced (Figures 2C and 2D). In contrast, the number
Figure 3. B5-I Neurons Express Dynorphin
(A) Spinal cord sections from P4mice (n = 3) were immunostained to reveal Bhlhb5 (green), PPD (red), and Pax2 (blue). Virtually all (99%, range 98%–100%) cells
expressing PPD and Pax2 were Bhlhb5 immunoreactive (arrows), and these accounted for the majority (85%, range 82.3%–87.95%) of B5-I cells at P4. Asterisk
indicates a B5-I cell that does not express PPD. Pax2-negative Bhlhb5-expressing cells (presumed excitatory cells) are indicated with arrowheads. Scale bar,
20 mm. Similar results were observed using antibodies directed against Dynorphin B (Figure S3).
(B) Spinal cord sections from 4- to 5-week-old wild-type (left) or Bhlhb5/ (right) mice immunostained for sst2A (green) and PPD (magenta). In wild-type mice,
dynorphin is expressed in a subset of sst2A-expressing neurons (arrows), whereas in Bhlhb5
/ mice, the sst2A-expressing neurons that remain lack dynorphin
(arrowheads). Images are single confocal optical sections.
(C) Quantification of (B) showing reduction in themean number of dynorphin-expressing cells in laminae I and II inBhlhb5/mice compared towild-type controls.
Data are represented as mean + SD number of cells per dorsal horn through 100 mm cord taken from L4 (n = 3 mice/genotype) and were analyzed by Student’s
t test (* indicates p < 0.05). Also see Figure S3.
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nNOS did not differ significantly between wild-type and
Bhlhb5/ mice. This analysis of sst2A-expressing interneurons,
together with the previous quantification of inhibitory neurons
that lack sst2A (Figure 1D), suggest that the galanin and nNOS
populations of inhibitory neurons are severely depleted in
Bhlhb5/ mice, whereas all other inhibitory populations are
unchanged.
B5-I Neurons Express the Kappa Opioid Dynorphin
The loss of galanin cells in the Bhlhb5/ mice was of particular
interest because these cells also express the kappa opioid dy-
norphin (Bro¨hl et al., 2008; Sardella et al., 2011), and there is pre-
cedent for the idea that kappa opioids inhibit itch (Inan and
Cowan, 2004; Ko et al., 2003; Togashi et al., 2002). We therefore
confirmed that dynorphin is expressed in B5-I neurons by react-
ing spinal cords from P4 mice with antibodies against Bhlhb5
and the dynorphin precursor, preprodynorphin (PPD; Figure 3A).
As expected, we found that virtually all dynorphin-expressing
neurons in laminae I-II were Bhlhb5 immunoreactive. We also
assessed the number of dynorphin-expressing inhibitory inter-
neurons in adult Bhlhb5/ animals with antibodies against
either PPD or dynorphin B, a cleavage product of the full-length
dynorphin peptide. These experiments revealed an almost com-
plete loss of dynorphin-expressing inhibitory interneurons in
Bhlhb5/mice (Figures 3B, 3C, S3B, S3A and S3C), consistent
with the finding that galanin-expressing neurons are largely
absent in these mice.
Kappa Opioids Inhibit Itch in Response to a Variety of
Pruritogens
The finding that Bhlhb5/ mice lack spinal inhibitory neurons
that release dynorphin raised the possibility that B5-I neurons
normally inhibit itch in part through activation of the kappa opioid
receptor (KOR). As a first step to test this idea, we investigated
the effect of kappa agonists nalfurafine and U-50,488 (Figure 4A;Morgan and Christie, 2011; Wikstro¨m et al., 2005; Williams et al.,
2013) on acute pruritogen-evoked itch behavior. To investigate
whether kappa agonists inhibit itch mediated by MrgprA3/C11-
expressing afferents, we quantified scratch bouts following intra-
dermal injection of chloroquine into the nape of the neck of mice
that had been pretreated with either nalfurafine (20 mg/kg) or
vehicle. We found that nalfurafine significantly reduced chloro-
quine-induced itch behavior (Figures 4B and 4C), consistent
with previous findings (Inan and Cowan, 2004). Likewise, nalfur-
afine significantly attenuated SLIGRL-mediated itch (Figure 4D).
To extend these observations, we tested the effect of U-50,488
(3 mg/kg), a molecularly distinct kappa opioid agonist and
observed a similar inhibition of chloroquine- and SLIGRL-
induced scratching (Figures 4B, 4C, and 4D). Thus, kappa ago-
nists inhibit itch mediated by MrgprA3/C11-expressing sensory
neurons.
Recent studies have revealed that histamine-induced itch is
different than chloroquine-induced itch in that it is mediated
by a distinct subset of primary afferents (Roberson et al.,
2013). We therefore tested the effect of KOR agonists on hista-
mine-induced itch and found that scratching behavior was
significantly reduced by nalfurafine, as previously reported
(Togashi et al., 2002), as well as by U-50,488 (Figure 4E). Simi-
larly, our experiments revealed that both nalfurafine and
U-50,488 significantly reduced serotonin-induced itch (Fig-
ure 4F). Finally, we investigated a dry skin model of itch that
develops following daily topical application of acetone/ether
followed by water (AEW) (Akiyama et al., 2010b; Miyamoto
et al., 2002). Both kappa agonists significantly reduced sponta-
neous scratching behavior produced by AEW treatment (Fig-
ure 4G). Importantly, neither U-50,488 (3 mg/kg) nor nalfurafine
(20 mg/kg) had any significant effect on rotarod performance,
indicating that their effects were not due to motor impairment
(Figure S4A). Thus, KOR agonists significantly abate various
types of pruritus, including histamine-dependent and hista-
mine-independent itch.Neuron 82, 573–586, May 7, 2014 ª2014 The Authors 577
Figure 4. Systemic Administration of U-50,488 or Nalfurafine Inhibits Scratching Behavior
(A) Molecular structure of two KOR agonists, U-50,488 and nalfurafine (also called TRK-820).
(B–F) Pretreatment with U-50,488 (3 mg/kg) or nalfurafine (20 mg/kg) significantly attenuates scratching following intradermal injection of chloroquine (200 mg)
(B and C), SLIGRL (100 nM) (D), Histamine (100 mg) (E), or 5-HT (30 mg) (F) relative to control (PBS). Data are represented as mean + SEM number of scratch bouts
during the first 40 min after pruritogen injection (n = 8mice/treatment). For (B), (D), (E), and (F), data were analyzed by one-way ANOVA and Tukey’s post hoc test;
*p < 0.05. For (C), data were analyzed by two-way ANOVA and Tukey’s post hoc test; significant effects (p < 0.05) of U-50,488 (*) and nalfurafine (#) are indicated.
(G) Spontaneous scratching induced by AEW treatment was significantly reduced in mice pretreated with either U-50,488 or nalfurafine compared to controls
receiving vehicle (PBS). Data are represented asmean + SEM number of scratch bouts recorded over a 1 hr observation period (n = 8mice/treatment). Data were
analyzed by one-way ANOVA and Tukey’s post hoc test; *p < 0.05.
(H) Pretreatment with nalfurafine (20 mg/kg) significantly attenuated chloroquine-induced scratching behavior in both wild-type (WT; #p < 0.05) and Bhlhb5/
(yp < 0.05) mice. * indicates significant difference (p < 0.05) in chloroquine-induced scratching between WT and Bhlhb5/ mice. Experiments were performed
using 4-week-old littermate pairs, prior to development of skin lesions (n = 8mice/treatment). Data were analyzed by two-way ANOVA and Tukey’s post hoc test.
(I) Itch sensitivity in constitutive preprodynorphin/ (PPD/) mice (Loacker et al., 2007) was analyzed by measuring the response to an intradermal injection of
chloroquine into the nape of the neck. Scratching behavior did not significantly differ between treatment groups (n = 7 mice/genotype), suggesting that PPD/
mice respond normally to acute pruritic stimuli. Data are represented as mean + SEM, and significance was assessed using a Student’s t test.
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opioid signaling, due to loss of dynorphin-expressing spinal
interneurons, contributes to the abnormally elevated itch in
Bhlhb5/ mice. Thus, we reasoned that exogenous KOR ago-
nists would relieve abnormal itch in these animals. As observed
previously, we found that intradermal injection of chloroquine578 Neuron 82, 573–586, May 7, 2014 ª2014 The Authorscaused significantly more scratching in Bhlhb5/ mice relative
to littermate controls (Figure 4H; Ross et al., 2010). Importantly,
pretreatment with nalfurafine almost completely abrogated
scratching behavior in Bhlhb5/ mice, consistent with the
idea that abnormally elevated itch responses in these mice are
partly due to decreased kappa tone in spinal cord (Figure 4H).
Figure 5. Kappa Agonists Selectively Inhibit
Itch- but Not Pain-Associated Behaviors
(A and B) The cheek model was used to discrimi-
nate between pain- (B) and itch-related (A) be-
haviors. Wiping the cheek with the forepaw
following an intradermal injection of a chemical
stimulus is indicative of pain, while scratching the
injection site with the hindlimb indicates itch.
(C) Intradermal chloroquine (100 mg) injected into
the cheek elicited robust hindlimb-mediated
scratching, and this was significantly attenuated in
mice pretreated with nalfurafine (20 mg/kg) com-
pared to control.
(D) Nalfurafine (20 mg/kg) had no significant effect
on chloroquine-evoked wiping behavior.
(E) Intradermal injection of capsaicin (30 mg) into
the cheek caused a small amount of hindlimb
scratching, which was significantly reduced by
nalfurafine (20 mg/kg).
(F) Nalfurafine (20 mg/kg) had no significant effect
on capsaicin-induced wiping. For (C)–(F), data are
shown asmean + SEM (n = 8mice/treatment); *p <
0.05, Student’s t test; NS indicates no significant
effect.
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itch in Bhlhb5/ mice was simply due to the loss of dynorphin,
or whether the absence of fast synaptic inhibition from B5-I neu-
rons was also involved. To test whether constitutive loss of dy-
norphin was sufficient for abnormally elevated itch, we analyzed
itch in mice lacking the dynorphin precursor PPD. We found that
PPD/ mice and their wild-type littermates showed no differ-
ence in pruritogen-induced itch behavior (Figure 4I). This obser-
vation suggests that the abnormally elevated itch observed in
Bhlhb5/mice is not due to loss of spinal dynorphin alone, hint-Neuron 82, 573ing at a key role for GABA and/or glycine
in the inhibition of itch by B5-I neurons.
A consequence of the loss of B5-I neu-
rons in Bhlhb5/mice is that these mice
develop spontaneous skin lesions due to
severe pathological itch. To test whether
treatment with KOR agonists might pro-
vide therapeutic relief for neuropathic
itch, we tested these drugs on Bhlhb5/
mice with pruritic skin lesions. Systemic
treatment with either U-50,488 or nalfura-
fine significantly reduced the amount of
time Bhlhb5/ mice spent biting and/or
licking the site of lesion by 33% ± 14%
and 40% ± 22%, respectively (Figures
S4B and S4C), suggesting that kappa
opioids have therapeutic potential for
neuropathic itch conditions.
Kappa Opioids Are Selective
for Itch
Because of the key role of mu opioids
in inhibition of pain, numerous groups
have assessed the potential role of KORagonists as analgesics (Kivell and Prisinzano, 2010; Vanderah,
2010). While KOR agonists were found to be analgesic in some
acute, inflammatory, and neuropathic pain tests, their analgesic
efficacy at doses that do not affect motor coordination remains
unclear (Leighton et al., 1988; Stevens and Yaksh, 1986). We
therefore wondered whether a concentration sufficient to inhibit
itch (i.e., 20 mg/kg of nalfurafine) is selective for pruritoception
rather than nociception. To address this question, we used the
cheek model (Figures 5A and 5B), in which pruritic agents elicit
scratching with the hindlimb, whereas nociceptive substances–586, May 7, 2014 ª2014 The Authors 579
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Akiyama et al., 2010a). As expected, intradermal injection of
chloroquine into the cheek induced robust hindlimb-mediated
scratching with minimal wiping behavior, indicative of itch. Sys-
temic pretreatment with nalfurafine led to an almost complete
suppression of scratching, with no significant effect on wiping
behavior (Figures 5C and 5D), in accordance with the idea that
kappa agonists inhibit itch.
Next, to investigate the effect of kappa agonists on nocicep-
tion, we injected capsaicin into the cheek. This treatment evoked
intense site-directed wiping with little scratching, in keeping with
the idea that pain is the predominant sensation elicited by capsa-
icin. Importantly, capsaicin-induced wiping was not affected by
pretreatment with nalfurafine (Figure 5F), suggesting that noci-
ceptive responses were unaffected by kappa opioid signaling.
In contrast, the modest scratching in response to capsaicin
was almost completely abolished following treatment with nal-
furafine (Figure 5E). These results suggest that kappa opioid
agonists, at least at low doses, can selectively inhibit itch with
no effect on pain.
KOR Agonists and Antagonists Bidirectionally Modulate
Itch at the Spinal Cord Level
The finding that systemic kappa opioids inhibit itch, together with
our discovery that Bhlhb5/ mice lack dynorphin-expressing
spinal interneurons, raised the possibility that endogenous dy-
norphin and exogenous kappa opioids modulate itch through
common neural circuits in the spinal cord. To test the idea that
the inhibition of itch by kappa opioids is due, at least in part, to
activation of spinal KORs, we manipulated KOR signaling in
the spinal cord through intrathecal delivery of KOR agonists.
Since intrathecal injections allowed us to target dermatomes
L3–L5 (corresponding to the hindlimbs), itch behavior was
assessed using the calf model (LaMotte et al., 2011), in which in-
jection of a pruritic agent into the skin elicits a biting response
(Figure 6A). Importantly, we found that intrathecal administration
of either U-50,488 (10 mg) or nalfurafine (40 ng) to the lumbar spi-
nal cord significantly reduced chloroquine-evoked biting (Fig-
ure 6B). These findings suggest that activation of KORs in the
spinal cord is sufficient to inhibit itch.
A key question is the identity of the cellular targets for kappa
opioids within the spinal cord. Though the central processing
of itch is not clearly understood, recent work has suggested
that itch information is sequentially relayed by at least two types
of spinal interneurons (Npra-expressing neurons followed by
GRPR-expressing neurons) before being transmitted to the brain
(Mishra and Hoon, 2013). We therefore investigated whether
kappa opioids act upstream or downstream of GRPR-express-
ing neurons by testing the effect of nalfurafine on GRP-mediated
itch. Intrathecal injection of GRP caused robust scratching that
was significantly reduced by nalfurafine (Figure 6C). This finding
suggests that kappa agonists mediate their effect (either directly
or indirectly) onGRPR-expressing neurons, or on neurons down-
stream of GRPR activation in the spinal cord.
Next, we reasoned that if B5-I neurons normally release dynor-
phin to inhibit itch, then blocking endogenous KOR signaling
in the dorsal horn might result in elevated itch. To test this
idea, we investigated whether treatment with the KOR antago-580 Neuron 82, 573–586, May 7, 2014 ª2014 The Authorsnists norbinaltorphimine (norBNI) or 50-guanidinonaltrindole
(50GNTI; Figure 6D) could trigger an enhanced response to chlo-
roquine in the calf. We found that chloroquine-induced biting
was significantly increased by intrathecal norBNI. Likewise treat-
ment with 50GNTI intrathecally increased the amount of chloro-
quine-induced biting relative to control (Figure 6E). The finding
that blocking KOR signaling increases itch response to chloro-
quine suggests that endogenous spinal dynorphin normally
functions to dampen itch. Together, these results show that
modulating opioid tone in the spinal cord can bidirectionally alter
itch sensitivity—increasing kappa opioid signaling causes
decreased itch, whereas decreasing kappa opioid signaling re-
sults in increased itch.
B5-I Neurons Mediate Inhibition of Itch by Chemical
Counterstimuli
In light of the finding that B5-I neurons function to inhibit itch, we
wished to characterize these cells in more detail. We performed
patch-clamp recordings from lamina II neurons genetically
labeled with the Bhlhb5-cre allele (Figure 7A). Since this allele
labels a somewhat broader population than those that we define
as B5-I neurons, we used hyperpolarization in response to
somatostatin to confirm that we were recording from B5-I neu-
rons. Four basic firing patterns can be identified in lamina II inter-
neurons in response to injection of depolarizing current: tonic,
delayed, phasic/transient, and single spiking (Graham et al.,
2007; Heinke et al., 2004; Ruscheweyh and Sandku¨hler, 2002).
We found that the majority (29 out of 34) of B5-I neurons showed
tonic firing (Figures 7B and S5A) and may therefore function as
integrators. Neurons can be classified based on morphology
and previous studies have described several types including ver-
tical, islet, central, and radial, although many cells cannot be
classified according to this scheme (Grudt and Perl, 2002;
Yasaka et al., 2007, 2010). To determine whether B5-I neurons
belonged to any of these subsets, we reconstructed B5-I neu-
rons. Though B5-I neurons did not fit strictly into a single class,
the majority were either central or unclassified, with axons and
dendrites mainly restricted to lamina II (Figure 7C). Thus, B5-I
neurons are likely to be involved in integrating sensory input
within the substantia gelatinosa.
One of the hallmarks of itch is that it is relieved by a variety
of counterstimuli, such as scratching, noxious chemicals, or
menthol (Bromm et al., 1995; Ward et al., 1996; Yosipovitch
et al., 2007). While the neural basis for this phenomenon is un-
known, it has been suggested that counterstimuli reduce itch
through activation of spinal inhibitory interneurons (Akiyama
et al., 2011; Ma, 2010; Patel and Dong, 2010; Ross, 2011; Bau-
tista et al., 2014). Based on our findings, B5-I neurons seemed
well positioned tomediate the inhibition of itch by counterstimuli.
If so, we reasoned that they would receive input (either directly or
indirectly) from primary afferents that mediate the counterstimuli.
Capsaicin, mustard oil, and menthol activate discrete subsets
of primary afferents (those that express TrpV1, TrpA1, and
TrpM8, respectively). Since topical treatment with any of these
substances can inhibit itch, we tested whether B5-I neurons
receive input from primary afferents that express TrpV1, TrpA1,
or TrpM8 (Figure 7D). Upon application of capsaicin to depo-
larize TrpV1-expressing afferents, we saw a significant increase
Figure 6. Modulation of Kappa Opioid Tone in the Spinal Cord Bidirectionally Modulates Itch Behavior
(A) The calf model was used to evaluate itch-related behaviors. In this model, a pruritogen is injected into the skin of the calf and biting is indicative of itch.
(B) Intrathecal administration of 10 mg U-50,488 or 40 ng nalfurafine (doses 60-fold lower than those used above for systemic administration) significantly reduced
chloroquine-induced biting. Data are presented as mean + SEM (n = 6–8 mice/treatment). * indicates significant difference (p < 0.05) between treatment and
control using one-way ANOVA and Tukey’s post hoc test.
(C) Nalfurafine significantly reduces GRP-induced itch behavior. Intrathecal GRP-evoked scratching behavior was significantly attenuated when GRP (0.1 nmol)
was coinjected with nalfurafine (40 ng) compared to PBS. Data are represented as mean + SEM number of scratch bouts recorded over a 30 min observation
period (n = 7 mice/treatment). Data were analyzed by a Student’s t test; * indicates p < 0.05.
(D) Molecular structure of two kappa opioid receptor antagonists, norbinaltorphimine (norBNI) and 50-guanidinonaltrindole (50GNTI).
(E) Chloroquine-induced biting was significantly elevated after intrathecal administration of the kappa opioid antagonists 50GNTI (1 mg) or nor-BNI (1 mg). Data are
presented as mean + SEM (n = 6–8 mice/treatment). * indicates significant difference (p < 0.05) between treatment and control using a one-way ANOVA and
Tukey’s post hoc test.
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rents (sEPSCs) in 80% (4 of 5) of B5-I neurons, with an average
7.8-fold increase in EPSC frequency (Figures 7E and 7F). More-
over, a significant increase in mEPSC frequency was likewise
observed in the presence of tetrodotoxin (TTX) to block action
potential propagation, suggesting that B5-I neurons receive
direct input from capsaicin-sensitive sensory neurons (Fig-
ure S5B). Similarly, allyl isothiocyanate, a key component of
mustard oil, resulted in increased sEPSC frequency in 86%
(6 out of 7) B5-I neurons, with an average increase of 3.3-fold
(Figures 7G and 7H). Finally we observed that sEPSC frequency
was also significantly increased 2.5-fold by menthol in 90%
(9 out of 10) of B5-I neurons (Figures 7I and 7J). Once again,
the increase in mEPSC frequency in response to capsaicin,
mustard oil, and menthol was also observed in the presence of
tetrodotoxin (TTX) to block action potentials, suggesting that
TrpA1- and TrpM8-expressing afferents directly innervate B5-I
neurons (Figures S5B, S5C, and S5D).The finding that B5-I neurons receive direct input from sensory
neurons that respond to capsaicin, mustard oil, and menthol is
consistent with the idea that B5-I neurons mediate the inhibition
of itch by chemical counterstimuli. To directly test this possibility,
we developed a mouse model of inhibition of itch by menthol.
When wild-type mice were treated with 8% menthol (topically)
on the cheek, this caused a significant reduction in subsequent
chloroquine-induced scratching. In contrast, Bhlhb5/ mice
showed no significant inhibition of itch by menthol (Figure 8A).
These findings suggest that B5-I neurons are required for the
inhibition of itch by menthol (Figure 8B).
DISCUSSION
While our everyday experience that itch is relieved by countersti-
mulation indicates that itch is under inhibitory control, the neural
basis for this phenomenon has remained obscure and neuromo-
dulators of itch have not been identified. Here we begin to shedNeuron 82, 573–586, May 7, 2014 ª2014 The Authors 581
Figure 7. B5-I Neurons Are Innervated by Sensory Neurons that
Respond to Capsaicin, Mustard Oil, and Menthol
(A) Bhlhb5-cre neurons were recorded in patch-clamp experiments; fluores-
cence (left) and IR-DIC (right) image. B5-I neurons had input resistances of
641.7 ± 71.7 MU and a resting membrane potential of 63.3 ± 1.4 mV. Every
neuron exhibited EPSCs at an average amplitude of 7.9 ± 0.6 pA at a holding
potential of 70 mV. No IPSCs were observed because the reversal potential
for IPSCs was near 70 mV.
(B) Representative firing pattern of B5-I neuron in response to depolarizing
current pulse of 25 (red) and 100 (black) pA.
(C) Morphology of B5-I neurons. Neurolucida reconstructions revealed that
most B5-I neurons are central (illustrated) or unclassified. Blue, dendrites; red,
axons.
(D) Schematic illustrating experimental setup to test whether B5-I neurons
receive input from TrpV1-, TrpA1-, or TrpM8-expressing neurons.
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582 Neuron 82, 573–586, May 7, 2014 ª2014 The Authorslight on this issue by identifying a neuronal subtype in the spinal
cord—B5-I neurons—that inhibits itch. We discover that B5-I
neurons correspond to specific neurochemical populations
and show that they are the major source of the endogenous
kappa opioid dynorphin in the dorsal horn. Our data suggest
that kappa opioids selectively inhibit itch without affecting
pain. Indeed, modulation of kappa opioid tone in the spinal
cord can bidirectionally control itch sensitivity, implying that
dynorphin acts as a neuromodulator. Finally, we demonstrate
that B5-I neurons are innervated by capsaicin-, mustard oil-,
and menthol-responsive primary afferents and are required for
inhibition of itch by menthol. These data suggest that B5-I neu-
rons mediate the inhibition of itch by chemical counterstimuli
(Figure 8B).
Dorsal Horn Interneurons
Inhibitory interneurons, which use GABA and/or glycine, ac-
count for 25%–30% of neurons in laminae I-II (Polga´r et al.,
2003, 2013b) and are thought to perform several distinct roles
in sensory processing (Hughes et al., 2012; Ross, 2011; Sand-
ku¨hler, 2009). To understand how these cells modulate
somatosensory input, it is essential to distinguish different func-
tional populations among them (Graham et al., 2007; Todd,
2010). The most widely accepted scheme for classifying super-
ficial dorsal horn interneurons was developed by Grudt and Perl
(2002), who identified four main groups, based largely on
morphological criteria. However, though others have used this
scheme, 30% of neurons in these studies could not be
classified based on morphology (Heinke et al., 2004; Maxwell
et al., 2007; Yasaka et al., 2007, 2010). Moreover, with the
exception of islet cells, inhibitory neurons are morphologically
diverse (Yasaka et al., 2010). Thus, morphology does not
appear to be particularly useful for defining inhibitory inter-
neuron subpopulations.
An alternative approach uses the wide array of neuropep-
tides, receptors, and other proteins that are differentially ex-
pressed by dorsal horn neurons (Polga´r et al., 2013a, 2013b).
We previously found that 50% of inhibitory cells in laminae
I-II express sst2A, and these can be further subdivided into
subpopulations that contain galanin and/or nNOS (which
constitute 60% of the sst2A-expressing cells and therefore
approximately one-third of all the inhibitory neurons). The gal-
anin cells coexpress PPD and are the major source of dynor-
phin in the superficial laminae (Bro¨hl et al., 2008; Sardella
et al., 2011). In addition, we identified two other nonoverlap-
ping groups among inhibitory interneurons that lack sst2A
(NPY- and parvalbumin-expressing cells). There is already
evidence that these neurochemical classes differ, both in their
responses to noxious stimuli and in their postsynaptic targets
(Todd, 2010; Hughes et al., 2012; Polga´r et al., 2013b). The
present results provide further evidence in support of this
classification scheme, since Bhlhb5/ mice show a loss of(E–J) Presynaptic effect of 2 mM capsaicin (E), 100 mM allyl isothiocyanate
(mustard oil) (G), and 500 mMmenthol (I). The majority of B5-I neurons showed
a significant increase in sEPSC frequency after bath application of capsaicin
(80%; F), mustard oil (86%; H), and menthol (90%; J). See Figure S5 for further
electrophysiological analysis of B5-I neurons.
Figure 8. B5-I NeuronsMediate Inhibition of
Itch by Chemical Counterstimuli
(A) Mice were treated topically on the cheek with
10 ml of either 8% menthol or PBS (control).
Menthol treatment resulted in modest wiping
behavior that ceased within 5 min. Ten minutes
after initial treatment, chloroquine (100 mg) was
injected intradermally into the cheek and hindlimb-
mediated scratching was quantified. Menthol
significantly reduced subsequent chloroquine-
induced scratching behavior in wild-typemice, but
not in Bhlhb5/ mice. Data are presented as
mean + SEM (n = 8 mice/treatment). * indicates
significant difference (p < 0.05) between treatment
and control using two-way ANOVA and Tukey’s
post hoc test. Note that there was also a significant difference in chloroquine-induced scratching as a function of genotype, as seen previously (Ross et al., 2010).
(B) Model: menthol-, capsaicin-, andmustard oil-sensitive sensory neurons inhibit itch via B5-I neurons in dorsal horn. B5-I neurons release GABA and/or glycine,
which may cause acute inhibition of itch, as well as dynorphin, which acts as an inhibitory neuromodulator. Though the postsynaptic targets of B5-I neurons are
not known, the finding that kappa agonists inhibit GRP-mediated itch implies that kappa opioids act on or downstream of GRPR neurons.
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chemically defined populations.
Identification and Characterization of B5-I Neurons
We find that B5-I neurons correspond to two (mostly nonover-
lapping) subpopulations—those that coexpress galanin and
dynorphin and those that express nNOS. The subpopulation of
B5-I neurons that expresses galanin/dynorphin likely uses
GABA as its fast transmitter (Simmons et al., 1995), whereas
the B5-I neurons that express nNOS are thought to release
GABA and glycine (Spike et al., 1993). Since relief of itch by
counterstimuli begins almost instantaneously, we favor the
idea that this component is mediated by fast-acting inhibitory
transmitters. In contrast, dynorphin, which modulates neuronal
activity via G protein-coupled receptors, may underlie pro-
longed suppression of itch.
A key finding from our study is that the loss of B5-I neurons
(which results in an almost complete absence of dynorphin in
the spinal cord) has a different phenotypic outcome than loss
of dynorphin alone. Thus, Bhlhb5/ mice show dramatically
elevated itch, whereas PPD/ mice display normal itch sensi-
tivity. This distinction implies that an organism can compensate
for the loss of dynorphin, but not for the loss of dynorphin-
expressing neurons in the dorsal horn. We speculate that neuro-
modulatory mechanisms may be particularly amenable to
homeostatic compensation (Doi and Ramirez, 2010). In keeping
with this idea, mice lacking either enkephalin or the mu opioid re-
ceptor have subtle pain phenotypes (Ko¨nig et al., 1996; Matthes
et al., 1996), despite the fact that mu opioids are among the
most effective analgesics. Adaptation also occurs in response
to chronic opioid overexposure, as shown by the tolerance
observed in humans and animal models following long-term
treatment with opioid analgesics (Morgan and Christie, 2011;
Williams et al., 2013). These examples underscore the idea
that the nervous system is robust in its ability to adjust neural cir-
cuit function over time when opioid neuromodulatory function is
abnormal. In contrast, neural circuits in the dorsal horn are
unable to normalize itch sensitivity when B5-I neurons are lack-
ing, emphasizing the fundamental requirement of this neuronal
subtype for the normal manifestation of itch.B5-I Cells Mediate the Inhibition of Itch by
Counterstimuli
The idea that spinal interneuronsare involved in sharpeningacuity
between sensorymodalities has been proposed by us and others
(Ma, 2010;Ross, 2011;Zhenget al., 2010;Prescott et al., 2014). In
keeping with this idea, conditional loss of VGLUT2 in subsets of
primary afferents resulted in mice showing decreased nocicep-
tive responses but heightened pruritic responses, suggesting a
role for inhibitory neurons in the suppression of itch by noxious
input (Lagerstro¨m et al., 2010; Liu et al., 2010). However, the spe-
cific identity of spinal interneurons that mediate this type of inhi-
bition was unknown. The B5-I neurons that we describe here
arewell suited for this role since they receive direct input frompri-
mary afferents that are known to suppress itch. In addition, we
now provide direct evidence that B5-I neurons suppress itch,
since acute inhibition of these cells results in spontaneous
scratching. Finally, we show that, whereas menthol inhibits itch
inwild-typemice, it does not do so inmice that lackB5-I neurons.
Together, these data suggest that B5-I neuronsmediate the inhi-
bition of itch by menthol and likely other chemical counterstimuli.
Our findings also suggest that specific neuromodulators may
be involved in selectively tuning different types of somatosen-
sory input. This has strong precedent elsewhere in the nervous
system, where kappa and mu and opioids have distinct (and
often opposing) neuromodulatory roles. In the limbic system,
mu opioids are euphoric while kappa opioids are dysphoric
(Pfeiffer et al., 1986; Schlaepfer et al., 1998). In the hypothala-
mus, mu and kappa opioids have opposing effects on body
temperature (Xin et al., 1997). Indeed, mu and kappa receptor-
expressing neurons have been found to inhibit one another
directly, thereby mediating the mutually antagonistic effects in
modulation of pain by the nucleus raphe magnus (Pan et al.,
1997). Now parallels are beginning to emerge in the spinal
cord, where mu agonists specifically target nociception, and
kappa agonists, as we show here, selectively inhibit itch.
Kappa Opioid Agonists as a Treatment for Pruritus
Pruritus is one of the most common adverse effects following
spinal administration of mu opioid agonists, affecting >50% of
patients receiving epidural morphine (Kjellberg and Trame`r,Neuron 82, 573–586, May 7, 2014 ª2014 The Authors 583
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coadministered to reduce the intensity of pruritus, but its use is
limited due to its antianalgesic effects (Abboud et al., 1990).
Interestingly, nalbuphine, a mixed kappa opioid agonist/mu
opioid antagonist, is extremely effective in reducing postopera-
tive pruritus (Liao et al., 2011). Unlike naltrexone, nalbuphine
does not significantly antagonize the analgesic effects of
epidural morphine. This suggests that the ability of nalbuphine
to reduce morphine-induced itch is largely due to its KOR
agonist activity. Consistent with this, KOR agonists have been
shown to reduce morphine-induced itch in monkey (Ko et al.,
2003). These findings raise the possibility that coadministration
of mu and kappa opioids (or the use of agonists with affinities
for both receptors) may offer pain relief without causing itch.
An important question raised by our study is the identity of the
dorsal horn neurons that respond to kappa opioids. KORs have
been detected on some neurons in laminae I-II (Arvidsson et al.,
1995), and approximately 15% of lamina II neurons are hyperpo-
larized by kappa opioids (Eckert and Light, 2002; Peckys and
Landwehrmeyer, 1999). While we do not yet know the identity
of these cells, our finding that GRP-evoked itch is attenuated
by nalfurafine is consistent with the idea that kappa opioids
directly inhibit GRPR-expressing spinal interneurons. Alterna-
tively, kappa opioids may act downstream, targeting as-yet-un-
identified interneurons or projection neurons that mediate itch.
Identifying the dorsal horn neuronal subtype(s) that express the
KORwill be of great interest, as these cells may represent a point
of convergence between neural circuits mediating itch and those
responsible for inhibition of itch by counterstimuli.
Several clinical trials have shown that nalfurafine is effective in
reducing itch in patients with chronic renal failure (Kumagai et al.,
2012; Wikstro¨m et al., 2005). Furthermore, nalfurafine is well
tolerated, and dysphoria is not reported even after 1 year of treat-
ment. Our study provides insight into the mechanism through
which kappa agonists inhibit itch, raising the possibility that
this class of drugs may be broadly applicable as antipruritics.
Thus, kappa agonists may have therapeutic potential for the
treatment of pruritus resulting from a wide range of dermatolog-
ical and systemic diseases.EXPERIMENTAL PROCEDURES
Animals and Behavioral Experiments
Most behavioral tests were carried out on 6- to 8-week-oldmale C57bl/6 mice.
Experiments that involved Bhlhb5/ mice (Ross et al., 2010) were performed
on 4- to 5-week-old mice that did not have skin lesions, unless otherwise
stated. To generate age-matched wild-type and Bhlhb5/ mice, we harem
mated Bhlhb5/+ mice and wild-type and Bhlhb5/ offspring from the result-
ing litters were used. In all experiments, the observer was blind to genotype
and/or treatment. The use of animals was approved by the Institutional Animal
Care and Use Committee of the University of Pittsburgh and/or the Ethical
Review Process Applications Panel of the University of Glasgow. Experiments
performed in A.J.T.’s lab were in accordance with the UK Animals (Scientific
Procedures) Act 1986. Further details are provided in the Supplemental Exper-
imental Procedures.
Immunocytochemistry
Immunocytochemistry was performed using standard protocols. The anti-
bodies used in the study are listed in Table S1, and details of image analysis
are given in the Supplemental Experimental Procedures.584 Neuron 82, 573–586, May 7, 2014 ª2014 The AuthorsElectrophysiology
Laminectomies were performed on 4- to 6-week-old mice was performed, and
the spinal cord was excised to prepare parasagittal or transverse slices. We
defined neurons as being sensitive to a particular drug when the synaptic
response was altered by more than ±50%. Biocytin-filled cells were recon-
structed with Neurolucida (MicroBrightField). Further details are provided in
the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2014.02.046.
AUTHOR CONTRIBUTIONS
A.P.K., X.C., C.R.F., G.M.H., C.S.B., and E.S.S. performed and analyzed
behavioral experiments with supervision from S.E.R. E.P., D.C., and S.S. per-
formed and analyzed immunohistochemical experiments with supervision
from A.J.T. J.H., L.M.S., and S.K. performed and analyzed electrophysiolog-
ical experiments with supervision from H.R.K. and S.E.R. H.N., C.S., M.W.,
T.F., and T.K. contributed reagents. A.P.K., E.P., J.H., L.M.S., A.J.T., and
S.E.R. wrote the paper.
ACKNOWLEDGMENTS
This researchwas supported byNIH grants R01 AR063772 andR21 AR064445
to S.E.R. and by grants to A.J.T. from the MRC (MR/L003430/1) and BBSRC
(BB/J001082). Part of this work was supported by a grant from the Rita Allen
Foundation to S.E.R., who is a Rita Allen Foundation Pain Scholar. Additional
funding came from the Virginia Kaufman Endowment Fund No. 1 of the
University of Pittsburgh to S.E.R., the Competitive Medical Research Fund of
Pittsburgh to S.E.R., a Whitehall Foundation Research Grant to S.E.R., and
the Wellcome Trust to A.J.T. We thank S. Fulton, L. De Souza, E. Burrage,
and R. Kerr for expert technical assistance, Dr. Z. Puska´r for helpful advice,
andDr. P.Ciofi for the gift of dynorphinB antibody.H.N. is apartial patent owner
of nalfurafine (WO 93/15081); all other authors declare no conflict of interest.
Accepted: February 25, 2014
Published: April 10, 2014
REFERENCES
Abboud, T.K., Lee, K., Zhu, J., Reyes, A., Afrasiabi, A., Mantilla, M., Steffens,
Z., and Chai, M. (1990). Prophylactic oral naltrexone with intrathecal morphine
for cesarean section: effects on adverse reactions and analgesia. Anesth.
Analg. 71, 367–370.
Akiyama, T., Carstens, M.I., and Carstens, E. (2010a). Differential itch- and
pain-related behavioral responses and m-opoid modulation in mice. Acta
Derm. Venereol. 90, 575–581.
Akiyama, T., Carstens, M.I., and Carstens, E. (2010b). Spontaneous itch in the
absence of hyperalgesia in a mouse hindpaw dry skin model. Neurosci. Lett.
484, 62–65.
Akiyama, T., Iodi Carstens, M., and Carstens, E. (2011). Transmitters and path-
ways mediating inhibition of spinal itch-signaling neurons by scratching and
other counterstimuli. PLoS ONE 6, e22665.
Arvidsson, U., Riedl, M., Chakrabarti, S., Vulchanova, L., Lee, J.H., Nakano,
A.H., Lin, X., Loh, H.H., Law, P.Y., Wessendorf, M.W., et al. (1995). The
kappa-opioid receptor is primarily postsynaptic: combined immunohisto-
chemical localization of the receptor and endogenous opioids. Proc. Natl.
Acad. Sci. USA 92, 5062–5066.
Bautista, D.M., Wilson, S.R., and Hoon, M.A. (2014). Why we scratch an itch:
the molecules, cells and circuits of itch. Nat. Neurosci. 17, 175–182.
Bro¨hl, D., Strehle, M., Wende, H., Hori, K., Bormuth, I., Nave, K.A., Mu¨ller, T.,
and Birchmeier, C. (2008). A transcriptional network coordinately determines
Neuron
Cellular Basis for the Inhibition of Itchtransmitter and peptidergic fate in the dorsal spinal cord. Dev. Biol. 322,
381–393.
Bromm, B., Scharein, E., Darsow, U., and Ring, J. (1995). Effects of menthol
and cold on histamine-induced itch and skin reactions in man. Neurosci.
Lett. 187, 157–160.
Doi, A., and Ramirez, J.M. (2010). State-dependent interactions between
excitatory neuromodulators in the neuronal control of breathing. J. Neurosci.
30, 8251–8262.
Eckert, W.A., 3rd, and Light, A.R. (2002). Hyperpolarization of substantia gelat-
inosa neurons evoked by mu-, kappa-, delta 1-, and delta 2-selective opioids.
J. Pain 3, 115–125.
Graham, B.A., Brichta, A.M., and Callister, R.J. (2007). Moving from an aver-
aged to specific view of spinal cord pain processing circuits. J. Neurophysiol.
98, 1057–1063.
Grudt, T.J., and Perl, E.R. (2002). Correlations between neuronal morphology
and electrophysiological features in the rodent superficial dorsal horn.
J. Physiol. 540, 189–207.
Han, L., Ma, C., Liu, Q., Weng, H.J., Cui, Y., Tang, Z., Kim, Y., Nie, H., Qu, L.,
Patel, K.N., et al. (2013). A subpopulation of nociceptors specifically linked to
itch. Nat. Neurosci. 16, 174–182.
Heinke, B., Ruscheweyh, R., Forsthuber, L., Wunderbaldinger, G., and
Sandku¨hler, J. (2004). Physiological, neurochemical and morphological prop-
erties of a subgroup of GABAergic spinal lamina II neurones identified by
expression of green fluorescent protein in mice. J. Physiol. 560, 249–266.
Hughes, D.I., Sikander, S., Kinnon, C.M., Boyle, K.A., Watanabe, M., Callister,
R.J., and Graham, B.A. (2012). Morphological, neurochemical and electro-
physiological features of parvalbumin-expressing cells: a likely source of
axo-axonic inputs in the mouse spinal dorsal horn. J. Physiol. 590, 3927–3951.
Inan, S., and Cowan, A. (2004). Kappa opioid agonists suppress chloroquine-
induced scratching in mice. Eur. J. Pharmacol. 502, 233–237.
Iwagaki, N., Garzillo, F., Polga´r, E., Riddell, J.S., and Todd, A.J. (2013).
Neurochemical characterisation of lamina II inhibitory interneurons that ex-
press GFP in the PrP-GFP mouse. Mol. Pain 9, 56.
Kivell, B., and Prisinzano, T.E. (2010). Kappa opioids and the modulation of
pain. Psychopharmacology (Berl.) 210, 109–119.
Kjellberg, F., and Trame`r, M.R. (2001). Pharmacological control of opioid-
induced pruritus: a quantitative systematic review of randomized trials. Eur.
J. Anaesthesiol. 18, 346–357.
Ko, M.C., and Naughton, N.N. (2000). An experimental itch model in monkeys:
characterization of intrathecal morphine-induced scratching and antinocicep-
tion. Anesthesiology 92, 795–805.
Ko, M.C., Lee, H., Song, M.S., Sobczyk-Kojiro, K., Mosberg, H.I., Kishioka, S.,
Woods, J.H., and Naughton, N.N. (2003). Activation of kappa-opioid receptors
inhibits pruritus evoked by subcutaneous or intrathecal administration of
morphine in monkeys. J. Pharmacol. Exp. Ther. 305, 173–179.
Ko¨nig, M., Zimmer, A.M., Steiner, H., Holmes, P.V., Crawley, J.N., Brownstein,
M.J., and Zimmer, A. (1996). Pain responses, anxiety and aggression in mice
deficient in pre-proenkephalin. Nature 383, 535–538.
Kumagai, H., Ebata, T., Takamori, K., Miyasato, K., Muramatsu, T., Nakamoto,
H., Kurihara, M., Yanagita, T., and Suzuki, H. (2012). Efficacy and safety of a
novel k-agonist for managing intractable pruritus in dialysis patients. Am. J.
Nephrol. 36, 175–183.
Lagerstro¨m, M.C., Rogoz, K., Abrahamsen, B., Persson, E., Reinius, B.,
Nordenankar, K., Olund, C., Smith, C., Mendez, J.A., Chen, Z.F., et al.
(2010). VGLUT2-dependent sensory neurons in the TRPV1 population regulate
pain and itch. Neuron 68, 529–542.
LaMotte, R.H., Shimada, S.G., and Sikand, P. (2011). Mouse models of acute,
chemical itch and pain in humans. Exp. Dermatol. 20, 778–782.
Leighton, G.E., Rodriguez, R.E., Hill, R.G., and Hughes, J. (1988). kappa-
Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal
administration in the rat. Br. J. Pharmacol. 93, 553–560.Liao, C.C., Chang, C.S., Tseng, C.H., Sheen, M.J., Tsai, S.C., Chang, Y.L., and
Wong, S.Y. (2011). Efficacy of intramuscular nalbuphine versus diphenhydra-
mine for the prevention of epidural morphine-induced pruritus after cesarean
delivery. Chang Gung Med. J. 34, 172–178.
Liu, Y., Abdel Samad, O., Zhang, L., Duan, B., Tong, Q., Lopes, C., Ji, R.R.,
Lowell, B.B., and Ma, Q. (2010). VGLUT2-dependent glutamate release from
nociceptors is required to sense pain and suppress itch. Neuron 68, 543–556.
Loacker, S., Sayyah, M., Wittmann, W., Herzog, H., and Schwarzer, C. (2007).
Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net
effect via kappa opioid receptors. Brain 130, 1017–1028.
Ma, Q. (2010). Labeled lines meet and talk: population coding of somatic sen-
sations. J. Clin. Invest. 120, 3773–3778.
Matthes, H.W.,Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I.,
Befort, K., Dierich, A., Le Meur, M., Dolle´, P., et al. (1996). Loss of morphine-
induced analgesia, reward effect and withdrawal symptoms in mice lacking
the mu-opioid-receptor gene. Nature 383, 819–823.
Maxwell, D.J., Belle, M.D., Cheunsuang, O., Stewart, A., and Morris, R. (2007).
Morphology of inhibitory and excitatory interneurons in superficial laminae of
the rat dorsal horn. J. Physiol. 584, 521–533.
Mishra, S.K., and Hoon, M.A. (2013). The cells and circuitry for itch responses
in mice. Science 340, 968–971.
Miyamoto, T., Nojima, H., Shinkado, T., Nakahashi, T., and Kuraishi, Y. (2002).
Itch-associated response induced by experimental dry skin in mice. Jpn. J.
Pharmacol. 88, 285–292.
Morgan, M.M., and Christie, M.J. (2011). Analysis of opioid efficacy, tolerance,
addiction and dependence from cell culture to human. Br. J. Pharmacol. 164,
1322–1334.
Nilsson, H.J., Levinsson, A., and Schouenborg, J. (1997). Cutaneous field stim-
ulation (CFS): a new powerful method to combat itch. Pain 71, 49–55.
Pan, Z.Z., Tershner, S.A., and Fields, H.L. (1997). Cellular mechanism for anti-
analgesic action of agonists of the kappa-opioid receptor. Nature 389, 382–385.
Patel, K.N., and Dong, X. (2010). An itch to be scratched. Neuron 68, 334–339.
Peckys, D., and Landwehrmeyer, G.B. (1999). Expression of mu, kappa, and
delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybrid-
ization study. Neuroscience 88, 1093–1135.
Pfeiffer, A., Brantl, V., Herz, A., and Emrich, H.M. (1986). Psychotomimesis
mediated by kappa opiate receptors. Science 233, 774–776.
Polga´r, E., Hughes, D.I., Riddell, J.S., Maxwell, D.J., Puska´r, Z., and Todd, A.J.
(2003). Selective loss of spinal GABAergic or glycinergic neurons is not neces-
sary for development of thermal hyperalgesia in the chronic constriction injury
model of neuropathic pain. Pain 104, 229–239.
Polga´r, E., Gray, S., Riddell, J.S., and Todd, A.J. (2004). Lack of evidence for
significant neuronal loss in laminae I-III of the spinal dorsal horn of the rat in the
chronic constriction injury model. Pain 111, 144–150.
Polga´r, E., Durrieux, C., Hughes, D.I., and Todd, A.J. (2013a). A quantitative
study of inhibitory interneurons in laminae I-III of the mouse spinal dorsal
horn. PLoS ONE 8, e78309.
Polga´r, E., Sardella, T.C., Tiong, S.Y., Locke, S., Watanabe, M., and Todd, A.J.
(2013b). Functional differences between neurochemically defined populations
of inhibitory interneurons in the rat spinal dorsal horn. Pain 154, 2606–2615.
Prescott, S.A., Ma, Q., and De Koninck, Y. (2014). Normal and abnormal cod-
ing of somatosensory stimuli causing pain. Nat. Neurosci. 17, 183–191.
Roberson, D.P., Gudes, S., Sprague, J.M., Patoski, H.A., Robson, V.K., Blasl,
F., Duan, B., Oh, S.B., Bean, B.P., Ma, Q., et al. (2013). Activity-dependent
silencing reveals functionally distinct itch-generating sensory neurons. Nat.
Neurosci. 16, 910–918.
Ross, S.E. (2011). Pain and itch: insights into the neural circuits of aversive
somatosensation in health and disease. Curr. Opin. Neurobiol. 21, 880–887.
Ross, S.E., Mardinly, A.R., McCord, A.E., Zurawski, J., Cohen, S., Jung, C.,
Hu, L., Mok, S.I., Shah, A., Savner, E.M., et al. (2010). Loss of inhibitory inter-
neurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice.
Neuron 65, 886–898.Neuron 82, 573–586, May 7, 2014 ª2014 The Authors 585
Neuron
Cellular Basis for the Inhibition of ItchRoss, S.E., McCord, A.E., Jung, C., Atan, D., Mok, S.I., Hemberg, M., Kim,
T.K., Salogiannis, J., Hu, L., Cohen, S., et al. (2012). Bhlhb5 and Prdm8 form
a repressor complex involved in neuronal circuit assembly. Neuron 73,
292–303.
Ruscheweyh, R., and Sandku¨hler, J. (2002). Lamina-specific membrane and
discharge properties of rat spinal dorsal horn neurones in vitro. J. Physiol.
541, 231–244.
Sandku¨hler, J. (2009). Models and mechanisms of hyperalgesia and allodynia.
Physiol. Rev. 89, 707–758.
Sardella, T.C., Polga´r, E., Garzillo, F., Furuta, T., Kaneko, T., Watanabe, M.,
and Todd, A.J. (2011). Dynorphin is expressed primarily by GABAergic neu-
rons that contain galanin in the rat dorsal horn. Mol. Pain 7, 76.
Schlaepfer, T.E., Strain, E.C., Greenberg, B.D., Preston, K.L., Lancaster, E.,
Bigelow, G.E., Barta, P.E., and Pearlson, G.D. (1998). Site of opioid action in
the human brain: mu and kappa agonists’ subjective and cerebral blood
flow effects. Am. J. Psychiatry 155, 470–473.
Seybold, V.S., Hylden, J.L., and Wilcox, G.L. (1982). Intrathecal substance P
and somatostatin in rats: behaviors indicative of sensation. Peptides 3, 49–54.
Shimada, S.G., and LaMotte, R.H. (2008). Behavioral differentiation between
itch and pain in mouse. Pain 139, 681–687.
Simmons, D.R., Spike, R.C., and Todd, A.J. (1995). Galanin is contained in
GABAergic neurons in the rat spinal dorsal horn. Neurosci. Lett. 187, 119–122.
Spike, R.C., Todd, A.J., and Johnston, H.M. (1993). Coexistence of NADPH
diaphorase with GABA, glycine, and acetylcholine in rat spinal cord.
J. Comp. Neurol. 335, 320–333.
Stevens, C.W., and Yaksh, T.L. (1986). Dynorphin A and related peptides
administered intrathecally in the rat: a search for putative kappa opiate recep-
tor activity. J. Pharmacol. Exp. Ther. 238, 833–838.
Sun, Y.G., Zhao, Z.Q., Meng, X.L., Yin, J., Liu, X.Y., and Chen, Z.F. (2009).
Cellular basis of itch sensation. Science 325, 1531–1534.
Szarvas, S., Harmon, D., andMurphy, D. (2003). Neuraxial opioid-induced pru-
ritus: a review. J. Clin. Anesth. 15, 234–239.
Tiong, S.Y., Polga´r, E., van Kralingen, J.C., Watanabe, M., and Todd, A.J.
(2011). Galanin-immunoreactivity identifies a distinct population of inhibitory
interneurons in laminae I-III of the rat spinal cord. Mol. Pain 7, 36.
Todd, A.J. (2010). Neuronal circuitry for pain processing in the dorsal horn. Nat.
Rev. Neurosci. 11, 823–836.
Todd, A.J., Spike, R.C., and Polga´r, E. (1998). A quantitative study of neurons
which express neurokinin-1 or somatostatin sst2a receptor in rat spinal dorsal
horn. Neuroscience 85, 459–473.586 Neuron 82, 573–586, May 7, 2014 ª2014 The AuthorsTogashi, Y., Umeuchi, H., Okano, K., Ando, N., Yoshizawa, Y., Honda, T.,
Kawamura, K., Endoh, T., Utsumi, J., Kamei, J., et al. (2002). Antipruritic activ-
ity of the kappa-opioid receptor agonist, TRK-820. Eur. J. Pharmacol. 435,
259–264.
Vanderah, T.W. (2010). Delta and kappa opioid receptors as suitable drug tar-
gets for pain. Clin. J. Pain 26 (Suppl 10 ), S10–S15.
Ward, L., Wright, E., andMcMahon, S.B. (1996). A comparison of the effects of
noxious and innocuous counterstimuli on experimentally induced itch and
pain. Pain 64, 129–138.
Weisshaar, E., and Dalgard, F. (2009). Epidemiology of itch: adding to the
burden of skin morbidity. Acta Derm. Venereol. 89, 339–350.
Wikstro¨m, B., Gellert, R., Ladefoged, S.D., Danda, Y., Akai, M., Ide, K.,
Ogasawara, M., Kawashima, Y., Ueno, K., Mori, A., and Ueno, Y. (2005).
Kappa-opioid system in uremic pruritus: multicenter, randomized, double-
blind, placebo-controlled clinical studies. J. Am. Soc. Nephrol. 16, 3742–3747.
Williams, J.T., Ingram, S.L., Henderson, G., Chavkin, C., von Zastrow, M.,
Schulz, S., Koch, T., Evans, C.J., and Christie, M.J. (2013). Regulation of
m-opioid receptors: desensitization, phosphorylation, internalization, and
tolerance. Pharmacol. Rev. 65, 223–254.
Xin, L., Geller, E.B., and Adler, M.W. (1997). Body temperature and analgesic
effects of selective mu and kappa opioid receptor agonists microdialyzed into
rat brain. J. Pharmacol. Exp. Ther. 281, 499–507.
Yasaka, T., Kato, G., Furue, H., Rashid, M.H., Sonohata, M., Tamae, A.,
Murata, Y., Masuko, S., and Yoshimura, M. (2007). Cell-type-specific excit-
atory and inhibitory circuits involving primary afferents in the substantia gelat-
inosa of the rat spinal dorsal horn in vitro. J. Physiol. 581, 603–618.
Yasaka, T., Tiong, S.Y., Hughes, D.I., Riddell, J.S., and Todd, A.J. (2010).
Populations of inhibitory and excitatory interneurons in lamina II of the adult
rat spinal dorsal horn revealed by a combined electrophysiological and
anatomical approach. Pain 151, 475–488.
Yosipovitch, G. (2008). Epidemiology of itching in skin and systemic diseases.
In Itch: Basic Mechanisms and Therapy, G. Yosipovitch, M.W. Greaves, A.B.
Fleischer, and F. McGlone, eds. (New York: Marcel Dekker), pp. 183–191.
Yosipovitch, G., Duque, M.I., Fast, K., Dawn, A.G., and Coghill, R.C. (2007).
Scratching and noxious heat stimuli inhibit itch in humans: a psychophysical
study. Br. J. Dermatol. 156, 629–634.
Zheng, J., Lu, Y., and Perl, E.R. (2010). Inhibitory neurones of the spinal sub-
stantia gelatinosa mediate interaction of signals from primary afferents.
J. Physiol. 588, 2065–2075.
